Programme

Our detailed interactive programme will be available here very soon.

All times are in Central European Summer Time (CEST).



 
 
Tuesday 19 October 2021
14:00-16:30

 
Plenary session 1: 2021 Opening session
Chairs: Hildegard Büning, Hannover Medical School 
Thierry VandenDriessche, VUBrussels
INV01: 
INV02: Ugur SahinBioNTech, Mainz
INV03: Mark Kay, Stanford University
INV04: Drew Weissman, University of Pennsylvania
 
16:30-17:00  
17:00-19:00 Session 1a: CNS & Sensory I
 
Chairs: 
INV05: 
INV06: Manny Simmons,
Akouos, Boston MA
INV07: Eri Hashino, Indiana University School of Medicine, Indianapolis

OR01:
OR02:
Session 1b: AAV as a gene therapy tool
from virus to vector

In memoriam - Mavis Agbandje-Mckenna
Chairs:

INV08: Dirk Grimm, Heidelberg University
INV09: Hildegard Büning, Hannover Medical School
INV10: Guangping Gao, University of Massachusetts
INV11: Aravind Asokan, Duke University School of Medicine, NC
 
Session 1c: CAR T & CAR NK cells
Chairs: 
INV12: Michael Hudecek, 

Universitätsklinikum Würzburg
INV13: Winfried Wels, Georg Speyer Haus, Frankfurt

OR03:
OR04:
OR05:
OR06:
 
Wednesday 20 October 2021
09:00-11:00 Session 2a: Primary immunodeficiencies
Chairs: 


INV14: Elena Almarza, Rocket Pharma, Madrid
INV15: Karin Pike Overzet, Leiden University
INV16: 

OR07:
OR08: 
Session 2b: Gene targeting
Chairs: 


INV17: Jacob Corn, ETH Zurich
INV18: Adi Barzel, Tel Aviv University

OR09:
OR10:

OR11:
OR12: 
Session 2c: Immunotherapy & CAR T cells
Chairs: 


INV19: Sonia Guedan, Idibaps, Barcelona
INV20: Bart Neyns, UZ Brussels

OR13: 
OR14:
OR15:
OR16:
11:00-11:30  
11:30-13:30
 
Plenary session 2: Advances in preclinical studies
Chairs: 

INV21: Luigi Naldini, SR Tiget, Milan
INV22: Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona
INV23: Alessia Cavazza, Institute of Child Health, UCLondon
INV24: Len Seymour, Oxford University
13:30-15:00 Sponsor workshops

15:00-17:00
Session 3a:  Liver & metabolic

Chairs: 

INV25: Alberto Auricchio, Tigem, Naples
INV26: Charles Venditti, NIH, NHGRI, Bethesda, MD

OR17:
OR18:
OR19:
OR20
Session 3b: Cardiovascular & lung diseases
Chairs: 

INV27: John Engelhardt, University of Iowa
INV28: Silva Priori, University of Pavia 
INV29: Seppo Ylä-Herttuala, Univeristy of Eastern Finland, Kuppio

OR21:
OR22: 
Session 3c: Muscle diseases

Chairs: 

INV30: Charles Gersbach, Duke University School of Medicine, NC
INV31: Isabelle Richard, Genethon, Evry
INV32: 

OR23: 

OR24: 

17:00- 17:30  
17:30-19:30 Plenary session 3: Gene therapy trials
Chairs: 
INV33: Alessandra Biffi, University of Padova, Harvard Stem Cell Institute
INV34: Chiara Bonini, Ospedale San Raffaele, Milan
INV35: 
INV36: 
 
Thursday 21 October 2021
9:00-11:00

 
Session 4a: CNS & sensory II
Chairs: 

INV37: Nathalie Cartier, Institut de la Moelle et du Cerveau, Paris
INV38: Jane Hughes, Gyroscope Therapeutics Limited, Stevenage
INV39: Deniz Dalkara, Institut de la vision, Paris

OR25: 

OR26: 

 
Session 4b:Gene editing I
Chairs: 

INV40: Anna Villa, SR Tiget, Milan
INV41: Manuel Gonçalves, Leiden University Medical Center

OR27: 

OR28:
OR29:
OR30 

 
Session 4c: Hematopoietic & bleeding disorders I
Chairs: 

INV42: Wolfgang Miesbach, Goethe University Hospital, Frankfurt
INV43: Alessio Cantore, SR Tiget, Milan

OR31: 

OR32:
OR33:
OR34 

10:30-11:00  
11:00-13:15

 
Plenary session 4: Presidential symposium
Chairs: Hildegard Büning, Juan Bueren


INV44: Hildegard Büning, Hannover Medical School
Presidential address

INV066: Hans Clevers, Utrecht University

INV45: Alessandro Aiuti, SR Tiget, Milan 
Else Kröner Fresenius Award


INV46: ESGCT Outstanding achievement award 


OR35: ESGCT Young Investigator award

 
13:15-14:45 Sponsor workshops
14:45-16:45 Session 5a: Non coding RNA
Chairs: 

INV47:  Stefanie Dimmeler, Goethe-University Frankfurt
INV48: 
INV49: Sandro Banfi, Tigem, Naples

OR36: 
OR37: 

 
Session 5b: Gene editing II
Chairs: 


INV50: Els Verhoeyen, University of Nice, ENS Lyon
INV51: Rodolfo Murillas, Ciemat, Madrid

OR38:
OR39:
OR40:
OR41:
Session 5c: Gene therapy:a bridge
to fight infectious diseases

Chairs: Mike McCune, Bill & Melinda Gates Foundtion


INV52: Frank Buchholz,TU Dresden
INV53: Luk Vandenberghe,
Harvard Medical School, MA
INV54: Scott Kitchen, UCLA

OR42: 
OR43: 
16:45-17:15  
17:15-19:15

 
Plenary session 5: Covid-19 & the risk of future zoonosis
Chairs: 

INV55: Shi Zhengli, Wuhan Institute of Virology
INV56: 
INV57: Derrick Rossi, Harvard University
INV58 
 
Friday 22 October 2021
09:00
11:00

 
Session 6a: Oncolytic viruses

Chairs: 

INV59: Tomoki Todo, The University of Tokyo
INV60: Victor Van Beusechem, Amsterdam UMC

OR44: 
OR45: 
OR46: 
OR47: 
Session 6b: Stem cells & regenerative medicine
Chairs: 

INV61: Maurillio Sampaolesi, KU Leuven
INV61: Cesar Nombela-Arrieta, University Hospital Zurich

OR48: 
OR49:
OR50:
OR51: 
Session 6c: Manufacturing

Chairs: 

INV62: Eduard Ayuso, Dinaqor, Pfäffikon 
INV63:
INV64: Stephen Howe,
GSK, Stevenage

OR52: 
OR53: 
11:00-11:30  
11:30-13:30 Session 5a: Safety

Chairs: 

INV65: Axel Schambach, Hannover Medical School
INV66: Ian Alexander, The University of Sydney

OR54: 
OR55: 
Session 5b:Patient perspective & regulatory
Chairs: 

INV67: 
INV68:
INV69:
INV70:

 
Session 5c: Late breaking abstracts

Chairs: 

 
13:30-15:00 Sponsor workshops
15:00
17:00
Session 6a: Hematopoietic & bleeding disorders II
Chairs: 

INV71: 
INV72: David Williams, Harvard Medical School, MA
INV73: Marina Cavazzana, Institut Imagine, HopitaL Necker, Paris

OR56: 
OR57: 
 
Session 6b: AAV immunology

Chairs: 

INV74: Yin Kai Chan, Harvard University
INV75: Giuseppe Ronzetti, Genethon, Evry

OR58: 
OR59:
OR60:
OR61: 
Session 6c: ASGCT

Chairs: 

INV76: 
INV77:
INV78:
INV79:
17:00-17:30  
17:30-19:30 Plenary session 6: Gene editing
Chairs: 

INV80: Dan Bauer, Harvard University
INV81: Julian Grunewald, Massachusetts General Hospital
INV82: Toni Cathomen, University of Freiburg
INV83: Sam Sternberg, Columbia University, NYC

Closing remarks

OUR SPONSORS

DIAMOND

European Society for Gene and Cell Therapy Sponsor

PLATINUM

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

GOLD

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

SILVER

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

BRONZE

European Society for Gene and Cell Therapy Sponsor

SUPPORTER